← Back to All US Stocks

AVCRF Stock Analysis - Avricore Health Inc. AI Rating

AVCRF OTC Pharmaceutical Preparations A1 CIK: 0001355736
Recently Updated • Analysis: Mar 20, 2026 • SEC Data: 2026-03-20
AI Rating
STRONG SELL
95% Confidence

📊 AVCRF Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence

Investment Thesis

Avricore Health Inc. presents an extremely high-risk profile due to complete absence of reportable financial data across all key metrics. With no revenue, no profitability, no balance sheet data, and zero insider activity, the company appears to be either pre-revenue, dormant, or non-operational. The lack of any measurable financial metrics makes fundamental analysis impossible and suggests either a shell company status or severe financial distress.

AVCRF Strengths

  • + Operates in pharmaceutical sector which has potential for value creation if development stage

AVCRF Risks

  • ! Complete absence of revenue and profitability data indicating non-operational status
  • ! No measurable balance sheet metrics - inability to assess financial solvency or liquidity
  • ! Zero insider activity suggesting lack of management confidence or engagement
  • ! No data freshness - cannot determine if company is active or defunct
  • ! Pharmaceutical development requires significant capital with high failure rates and extended time to commercialization

Key Metrics to Watch

AVCRF Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

AVCRF Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

AVCRF vs Healthcare Sector

How Avricore Health Inc. compares to Healthcare sector averages

Net Margin
AVCRF 0.0%
vs
Sector Avg 12.0%
AVCRF Sector
ROE
AVCRF 0.0%
vs
Sector Avg 15.0%
AVCRF Sector
Current Ratio
AVCRF 0.0x
vs
Sector Avg 2.0x
AVCRF Sector
Debt/Equity
AVCRF 0.0x
vs
Sector Avg 0.6x
AVCRF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

AVCRF Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

AVCRF Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

AVCRF SEC Filings

Access official SEC EDGAR filings for Avricore Health Inc. (CIK: 0001355736)

Frequently Asked Questions about AVCRF

What is the AI rating for AVCRF?

Avricore Health Inc. (AVCRF) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are AVCRF's key strengths?

Operates in pharmaceutical sector which has potential for value creation if development stage.

What are the risks of investing in AVCRF?

Complete absence of revenue and profitability data indicating non-operational status. No measurable balance sheet metrics - inability to assess financial solvency or liquidity.

What is AVCRF's revenue and growth?

Avricore Health Inc. reported revenue of N/A.

Does AVCRF pay dividends?

Avricore Health Inc. does not currently pay dividends.

Where can I find AVCRF SEC filings?

Official SEC filings for Avricore Health Inc. (CIK: 0001355736) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AVCRF's EPS?

Avricore Health Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2026-03-20 | Powered by Claude AI